Investigational drug · Phase 3
Limertinib
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for EGFR Activating Mutation, Non-Squamous Non-Small Cell Lung Cancer (NSCLC), MET Positive.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
9
Any phase or sponsor naming "Limertinib"
First trial start
2025
Aug 4, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Limertinib", any sponsor or status.
Conditions studied
As listed on its trial records.
- EGFR Activating Mutation
- Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- MET Positive
- Locally Advanced or Metastatic NSCLC
- Solid Tumor
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "Limertinib" as an intervention, largest first.
- ASKC202 Plus Limertinib as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLCPivotal-lookingNot yet recruiting
Jiangsu Aosaikang Pharmaceutical Co., Ltd.Industry
NCT07897188 · 425 participants (planned) · Start Oct 30, 2026 · Primary completion Dec 30, 2030
Drug: ASKC202; ASKC202 placebo and 6 more · For: EGFR Activating Mutation; Non-Squamous Non-Small Cell Lung Cancer (NSCLC); MET Positive
Sites: Shanghai, China
- ASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI TherapyPivotal-lookingRecruiting
Jiangsu Aosaikang Pharmaceutical Co., Ltd.Industry
NCT07109531 · 286 participants (planned) · Start Aug 4, 2025 · Primary completion Oct 31, 2027
Drug: ASKC202+ Limertinib; Pemetrexed + Cisplatin /Carboplatin · For: Locally Advanced or Metastatic NSCLC
Sites: Shanghai, China
- Study of IBI3005 Combination Therapy in Participants With Unresectable, Locally Advanced or Metastatic Solid TumorsNot yet recruiting
Innovent Biologics (Suzhou) Co. Ltd.Industry
NCT07612137 · 282 participants (planned) · Start Jun 1, 2026 · Primary completion Jun 30, 2027
Drug: IBI3005; Sintilimab and 4 more · For: Solid Tumor
Sites: Guangzhou, China
Jiangsu Aosaikang Pharmaceutical Co., Ltd.Industry
NCT05306132 · 150 participants (planned) · Start Aug 8, 2022 · Primary completion Dec 2026
Drug: ASKC202; ASK120067 · For: Advanced Solid Tumor
Sites: Zhengzhou, China; Changsha, China; Shanghai, China
- A Clinical Study on the Efficacy and Safety of the Combination of Limertinib and Bevacizumab Versus Limertinib as First-line Treatment for NSCLC.Pivotal-lookingNot yet recruiting
Shanghai Chest HospitalAcademic, hospital or other
NCT06982924 · 136 participants (planned) · Start Jun 30, 2025 · Primary completion Dec 30, 2026
Drug: Limertinib+bevacizumab; Limertinib · For: EGFR Mutation Positive Advanced Non Small Cell Lung Cancer; PD-L1 Positive
- A Multicenter Phase II Randomized Trial of Limertinib Followed by Sintilimab and Chemotherapy vs. Limertinib Followed by Limertinib and Chemotherapy as Neoadjuvant Therapy in Resectable Stage II-IIIB EGFR-Mutant NSCLCPivotal-lookingNot yet recruiting
Wen-zhao ZHONGAcademic, hospital or other
NCT07038460 · 134 participants (planned) · Start Jul 2025 · Primary completion Dec 2027
Drug: Limertinib+sintilimab+chemotherapy; Limertinib+chemotherapy and 1 more · For: Resectable Non-small Cell Lung Cancer
Sites: Guangzhou, China; Changsha, China; Hangzhou, China · 6 sites in all
- Limertinib Plus Radiotherapy for EGFR-Mutant NSCLC With Brain MetastasesNot yet recruiting
The First Affiliated Hospital of Guangzhou Medical UniversityAcademic, hospital or other
NCT07413952 · 45 participants (planned) · Start Apr 1, 2026 · Primary completion Dec 31, 2027
Drug: Limertinib Plus Radiotherapy · For: NSCLC
Sites: Guangzhou, China
Shanghai Pulmonary Hospital, Shanghai, ChinaAcademic, hospital or other
NCT07323056 · 36 participants (planned) · Start Jan 1, 2026 · Primary completion Jun 1, 2026
Drug: Sacituzumab Tirumotecan and Limertinib · For: EGFR-mutant Non-small Cell Lung Cancer; Potentially Resectable
Sites: Shanghai, China
- Limertinib Plus Carboplatin and Etoposide for EGFR-mutant NSCLC With SCLC Transformation After EGFR-TKI ProgressionNot yet recruiting
Hunan Province Tumor HospitalAcademic, hospital or other
NCT07001995 · 30 participants (planned) · Start May 1, 2026 · Primary completion Dec 30, 2027
Drug: limertinib; etoposide and carboplatin · For: Small Cell Lung Cancer; Non Small Cell Lung Cancer; Non Small Cell Lung Cancer NSCLC
Sites: Changsha, China
Newest research
PubMed records naming it or its code names, newest first.
- First-line third-generation EGFR-TKIs for advanced EGFR-mutated non-small cell lung cancer: a systematic review and network meta-analysis of randomized controlled trials.
Liu X, Zhao Q, Sun W, et al. · J Thorac Dis 2026
- Sphingosine-1-Phosphate Receptor 3 Confers Tumor Metastasis in Lung Cancer Resistant to Third-Generation EGFR Inhibitor.
Lai M, Chen J, Qin Y, et al. · MedComm (2020) 2026
- Epidermal growth factor receptor tyrosine kinase inhibitor for the treatment of non-small cell lung cancer in the past 30 years (1997-2026).
Xie Z, Chen X, Gao R, et al. · Chin Med J (Engl) 2026
- Chemical Adaptation in Drug Discovery: The Medicinal Chemistry Journey of Olverembatinib and Limertinib in Overcoming Kinase Drug Resistance.
Ding K, Li Y, Zhou Y, et al. · Acc Chem Res 2025
- Limertinib for EGFR mutation-positive NSCLC treatment.
Xia Y, Li MSC · Lancet Respir Med 2025
- Efficacy and safety of limertinib versus gefitinib as first-line treatment for locally advanced or metastatic non-small-cell lung cancer with EGFR-sensitising mutation: a randomised, double-blind, double-dummy, phase 3 trial.
Shi Y, Wu L, Ji Y, et al. · Lancet Respir Med 2025
Also in development for EGFR Activating Mutation
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.